Title: Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing

Author: Xuefei Zhang Yanlin Li Changhong Liu Weifeng Wang Mo Li Desheng Lv Ge Sun Hui Chen Xiaowei Dong Zhibo Miao Ming Yao Kai Wang Hui Tian

PII: S0169-5002(17)30492-0
DOI: http://dx.doi.org/doi:10.1016/j.lungcan.2017.08.019
Reference: LUNG 5456

To appear in: *Lung Cancer*

Received date: 11-5-2017
Revised date: 7-8-2017
Accepted date: 21-8-2017

Please cite this article as: Zhang X, Li Y, Liu C, Wang W, Li M, Lv D, Sun G, Chen H, Dong X, Miao Z, Yao M, Wang K, Tian H, Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing, *Lung Cancer* (2017), http://dx.doi.org/10.1016/j.lungcan.2017.08.019

Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing

Xuefei Zhang[1,2], Yanlin Li[3], Changhong Liu[2], Weifeng Wang[3], Mo Li[2], Desheng Lv[2], Ge Sun[2], Hui Chen[3], Xiaowei Dong[3], Zhibo Miao[3], Ming Yao[3], Kai Wang[3,4], Hui Tian[1,*]

[1]Department of Thoracic Surgery, Qilu Hospital of Shandong University Ji'nan City, Shandong province, China, 250012
[2]Department of Thoracic Surgery, The Second Hospital of Dalian Medical University, Dalian City, Liaoning Province, China, 116023
[3]OrigiMed, Shanghai, China
[4]Center for Precision Medicine, Zhejiang University International Hospital, Hangzhou, Zhejiang, China

*Corresponding Author:

Conflict of interest

YL, WW, HC, XD, MY, KW are employees of OrigiMed.

Highlights

- RET fusions have been reported in 1-2% of lung adenocarcinomas.
- RET fusion are associated with clinical benefit from multi-kinase inhibitors.
- We describe a novel RET-fusion in lung adenocarcinomas by NGS.
- NGS provide more comprehensive breakpoint information on partner genes
- The new RET fusions have immediate clinical implications.